Compare Davita Inc (DVA) vs Marvell Technology Inc (MRVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Marvell Technology Inc — how do they compare? Davita Inc trades at $178.5 (market cap $11.38B), while Marvell Technology Inc trades at $223.15 (market cap $190.56B). The key difference: Marvell Technology Inc is far larger — about 16.7× Davita Inc's market cap, and Marvell Technology Inc pays a 0.11% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | MRVL | |
|---|---|---|
Market Cap | $11.38B | $190.56B |
Sector | Health | Technology |
52-Week High | $240.96 | $316.43 |
52-Week Low | $103.87 | $62.31 |
Enterprise Value | $24.10B | $191.99B |
Dividend Yield | — | 0.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.69, down slightly by 0.04% over the past day. The stock shows strong fundamental performance with consistent earnings beats in recent quarters, including Q2 2026 EPS of $4.02 versus $3.88 expected (Zacks Investment Research, 2026-08-04). However, technical indicators signal a bearish trend, with the price near key support at $182. Revenue growth remains steady, climbing to $13.64 billion in 2025, though net income margin dipped to 5.47%.
The outlook is mixed; analyst consensus leans bullish with a $232.25 price target (MarketBeat, 2026-08-05), but risks include reimbursement pressure and high debt levels. Investment appeal hinges on execution against guidance amid payer-mix challenges, with the current valuation offering potential upside if operational trends stabilize.
Marvell Technology (MRVL) trades at $208.56, down 4.65% on the day, amid a broader semiconductor sell-off. The stock shows a bullish technical signal with support near $201 and resistance at $223. Fundamentally, while recent quarters have seen EPS beats, the company reported a net loss of $885 million for 2025, though revenue grew to $5.77 billion. Analyst sentiment remains strongly positive with an 82% buy rating and a $275.68 consensus price target, citing AI infrastructure growth drivers.
The outlook for MRVL is supported by its positioning in AI data center and optical networking markets, with partnerships like NVIDIA and Microsoft's Maia 300 offering significant upside. Key risks include intense competition, margin pressures, and geopolitical supply chain disruptions. Investors should weigh the high valuation multiples against the potential for AI-driven revenue acceleration in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →
